Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary<a href="https://solaci.org/en/2024/07/12/ultimate-iii-use-of-ivus-for-coronary-de-novo-lesion-drug-coated-balloon-angioplasty/" title="Read more" >...</a>
Intravascular Lithotripsy: Outcomes and Trends in the Treatment of Calcified Coronary Lesions
Lately, the complexity of percutaneous coronary artery interventions (PCI) has seen an increase, mainly driven by the increasing prevalence of coronary lesion calcification, which represents a significant challenge for interventionists. Untreated calcification might result in insufficient stent expansion, a high risk factor of thrombosis and instent restenosis. Historically, several devices have been used to treat<a href="https://solaci.org/en/2024/07/12/intravascular-lithotripsy-outcomes-and-trends-in-the-treatment-of-calcified-coronary-lesions/" title="Read more" >...</a>
Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk
Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the first line of treatment. A fundamental aspect is activation and platelet aggregation, which is why, in addition to creating networks to optimize STEMI treatment, prehospital drug treatments have been implemented. The COMPARECrush looked at whether early and powerful<a href="https://solaci.org/en/2024/07/08/prehospital-crushed-vs-integral-prasugrel-in-stemi-patients-with-large-myocardial-area-at-risk/" title="Read more" >...</a>
Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis
Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As<a href="https://solaci.org/en/2024/07/02/biolimus-vs-paclitaxel-coated-balloons-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>
2 Year Outcomes of Transcatheter Mitral Valve Replacement with Intrepid
Severe mitral valve insufficiency (MI) has been associated to the progressive deterioration of left ventricular function, cardiac and kidney failure, and increased mortality. Complete medical treatment at maximal doses and surgery are indicated. For those at high risk or those with ventricular function deterioration, edge-to-edge repair has been shown an excellent alternative. The use of<a href="https://solaci.org/en/2024/07/02/2-year-outcomes-of-transcatheter-mitral-valve-replacement-with-intrepid/" title="Read more" >...</a>
Glycemic Control and Coronary Stent Failure
Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>
BIONYX: Onyx vs. Orsiro At 5 Years
Onyx is a zotarolimus-eluting stent (ZES), designed with thin struts and a platinum core that enhances its radiological visibility. This can be beneficial in complex situations with limited visibility, such as in patients who are obese or present severe calcification, two particularly frequent characteristics in diabetic or elderly patients. The BIONYX study was a randomized<a href="https://solaci.org/en/2024/06/05/bionyx-onyx-vs-orsiro-at-5-years/" title="Read more" >...</a>
TAVR vs SAVR in Los Risk Patients: 10-Year Outcomes of the NOTION Trial
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR in patients at prohibitive surgical risk, as well as high and intermediate risk. The NOTION trial (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR and<a href="https://solaci.org/en/2024/05/28/tavr-vs-savr-in-los-risk-patients-10-year-outcomes-of-the-notion-trial/" title="Read more" >...</a>
EuroPCR 2024 | CALIPSO: CTO vs Angiography Guided Treatment of Calcified Lesions
The presence of calcified lesions worsens percutaneous coronary intervention prognosis, presenting more restenosis, thrombosis and need for new revascularization. The aim of this study was to assess the superiority of CTO with a prespecified management algorithm on a conventional angiography treatment, in addition to assessing CTO safety. A superiority randomized study was carried out including<a href="https://solaci.org/en/2024/05/17/europcr-2024-calipso-cto-vs-angiography-guided-treatment-of-calcified-lesions/" title="Read more" >...</a>
Catheter-Based Therapy for Pulmonary Embolism: Lower Mortality and Rehospitalization?
Venous thromboembolism represents one of the main causes of cardiovascular death. Pulmonary embolism (PE) can vary from asymptomatic to manifesting with shock and sudden death, with a wide clinical spectrum. Patient followup is crucial, seeing as survival PE patients usually experience residual symptoms at long term, such as dyspnea or functional capacity deterioration. For decades,<a href="https://solaci.org/en/2024/05/13/catheter-based-therapy-for-pulmonary-embolism-lower-mortality-and-rehospitalization/" title="Read more" >...</a>